Top Markets
Coin of the day
EQRx, Inc. EQRx, Inc.

EQRx, Inc.

EQRX
Classement en actions #11212
EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating... EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.
Prix de l'action
$2.34
Dernière synchronisation: 2023-11-09
Capitalisation boursière
$728.90M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange EQRx, Inc. (EQRX)

Catégorie

Historique du prix de l'action pour EQRx, Inc. (EQRX)
Prix de clôture le plus élevé : $2.36 le 2023-11-01

Prix de clôture le plus bas : $10.24 le 2021-06-01
Historique du prix de l'action de EQRx, Inc. de 2021 à 2026
Performance annuelle du prix de l'action
Année Performance
2023 -10.70%
2022 -68.78%
2021 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.53 -12.70%
AU
$138.18 473.58%
US
$759.27 7.20%
CH